Arcturus Therapeutics Net Income From Continuing Ops Over Time
| ARCT Stock | USD 17.51 0.58 3.43% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Arcturus Therapeutics Performance and Arcturus Therapeutics Correlation. Arcturus |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcturus Therapeutics. If investors know Arcturus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcturus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.33) | Revenue Per Share 5.955 | Quarterly Revenue Growth (0.08) | Return On Assets (0.12) | Return On Equity (0.23) |
The market value of Arcturus Therapeutics is measured differently than its book value, which is the value of Arcturus that is recorded on the company's balance sheet. Investors also form their own opinion of Arcturus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Arcturus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcturus Therapeutics' market value can be influenced by many factors that don't directly affect Arcturus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcturus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcturus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcturus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income From Continuing Ops Analysis
Compare Arcturus Therapeutics and related stocks such as 89bio Inc, Madrigal Pharmaceuticals, and Pliant Therapeutics Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ETNB | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (57.4 M) | (49.5 M) | (90.1 M) | (102 M) | (126.6 M) | (120.2 M) |
| MDGL | (47.4 M) | (47.4 M) | (62.8 M) | (90.2 M) | (86.2 M) | (68.7 M) | (26.4 M) | (31.5 M) | (33 M) | (83.9 M) | (202.3 M) | (242.1 M) | (295.4 M) | (373.6 M) | (354.9 M) |
| PLRX | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (631 K) | (41.5 M) | (97.3 M) | (123.3 M) | (155.3 M) | (147.5 M) |
| ACLX | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (32.1 M) | (65 M) | (188.7 M) | (129.5 M) | (136 M) |
| STOK | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (12.5 M) | (32.3 M) | (52.2 M) | (85.8 M) | (101.1 M) | (103.4 M) | (98.2 M) |
| NTLA | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (12.4 M) | (31.6 M) | (67.5 M) | (85.3 M) | (99.5 M) | (134.5 M) | (267.8 M) | (474.2 M) | (481.2 M) | (457.1 M) |
| BEAM | (116.7 M) | (116.7 M) | (116.7 M) | (116.7 M) | (116.7 M) | (116.7 M) | (116.7 M) | (116.7 M) | (116.7 M) | (78.3 M) | (194.6 M) | (370.6 M) | (289.1 M) | (313.7 M) | (329.4 M) |
| CRBU | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (34.3 M) | (66.9 M) | (99.4 M) | (94.6 M) | (99.3 M) |
| CRSP | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (25.8 M) | (23.2 M) | (68.4 M) | (165 M) | 66.9 M | (348.9 M) | 377.7 M | (650.2 M) | (153.6 M) | (161.3 M) |
| FATE | (20.9 M) | (20.9 M) | (20.9 M) | (20.9 M) | (25.9 M) | (30 M) | (33.5 M) | (43 M) | (66.6 M) | (98.1 M) | (173.4 M) | (212.2 M) | (281.7 M) | (173.2 M) | (164.5 M) |
| BPMC | (40.3 M) | (40.3 M) | (40.3 M) | (40.3 M) | (40.3 M) | (52.8 M) | (72.5 M) | (148.1 M) | (281.2 M) | (414.2 M) | 313.9 M | (644.1 M) | (557.5 M) | (554.7 M) | (527 M) |
| DAWN | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (43.8 M) | (72.8 M) | (142.2 M) | (188.9 M) | (179.5 M) |
| BMEA | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (5.3 M) | (41.6 M) | (81.8 M) | (117.3 M) | (111.4 M) |
| AKRO | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (81.7 M) | (43.8 M) | (79.2 M) | (100.8 M) | (112 M) | (119.6 M) | (125.6 M) |
| GOSS | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (6.8 M) | (147 M) | (180.3 M) | (243.4 M) | (234 M) | (229.4 M) | (187.4 M) | (196.8 M) |
| BDTX | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (8.9 M) | (35.3 M) | (67.3 M) | (125.6 M) | (91.2 M) | (82.4 M) | (86.6 M) |
| FDMT | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (9.6 M) | (49.3 M) | (56.7 M) | (71.3 M) | (107.5 M) | (95.9 M) | (91.1 M) |
Arcturus Therapeutics and related stocks such as 89bio Inc, Madrigal Pharmaceuticals, and Pliant Therapeutics Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Arcturus Therapeutics Holdings | ARCT |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 17.51
Additional Tools for Arcturus Stock Analysis
When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.